Today, we announced the outcomes of our End-of-Phase 2 meeting and shared the topline interim Phase 2 data for BOT/BAL in MSS colorectal cancer. Get the latest details here: https://lnkd.in/eH-sx85G
About us
Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or follow us at @agenus_bio. Our Community Guidelines are available at our website and at: https://agenusbio.com/community-guidelines/
- Website
-
https://agenusbio.com/.
External link for Agenus
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Lexington, Massachusetts
- Type
- Public Company
- Founded
- 1994
- Specialties
- Immuno-oncology, Cancer Vaccines, Checkpoint Inhibitors and Modulators, Immunotherapy, Cell therapy, Antibodies, and GMP Manufacturing
Locations
-
Primary
3 Forbes Road
Lexington, Massachusetts 02421, US
Employees at Agenus
Updates
-
Congratulations to our own Alexa Buffa on being named one of 2024's Industry Rising Stars at the Pharma PR and Communications Summit by Fierce Life Sciences Events!
Day 2 of the Pharma PR and Communications Summit is here, spotlighting our rising stars in the industry. These 14 talented individuals are recognized for their exceptional contributions and potential in shaping the future of pharmaceutical communications. They bring fresh perspectives, innovative ideas, and a passion for advancing the industry through their work and insights. Discover more about them here: https://ow.ly/31EK50SxZCI Big Shout Out to the 2024 Rising Stars: Daniel Haro from Biogen , Katie Hooker from Astria Therapeutics, Inc. , Mina Sabet from Amgen, Ingrid Medina from Merck, Kaitlyn Fiery from Alexion Pharmaceuticals, Inc., Jonni Mills from Click Therapeutics, Inc., Gabrielle Parzygnat, MBA from STAQ Pharma, Kerry Faust from AbbVie, Shey Ng Modh from Regeneron, Lena Ceballos from Arcturus Therapeutics, Emily Dale from Bitterroot Bio, Alexa Buffa from Agenus, Madison B. from MTEC | Medical Technology Enterprise Consortium, Jiayi (Janice) H. from Henlius and Sarah Flynn from Teva Pharmaceuticals. AND our Conference Producer Michelle Benz and Rising Stars' Advisor Lynnea Olivarez from Ticket to Biotech for all their hard work developing an incredible Rising Stars Program! Learn more about #FiercePharmaPR: https://ow.ly/XYLh50SxZCJ Stay Updated on all our events by following Fierce Life Sciences Events & join our Mailing List to be the first to know about the Rising Stars Program for 2025 ➡️ https://ow.ly/GbSA50Sy062 #WeAreFierce #publicrelations #pharmaceuticals #communications #pharma #FierceEvents #fiercepharma
-
Did you know immunotherapy activates the body’s own immune system to fight cancer? Agenus Chief Medical Officer, Dr. Steven O'Day, explains why this innovative approach stands apart from traditional chemotherapy.
-
Thank you to GI Oncology Now and Dr. Ben Schlechter of Dana-Farber Cancer Institute for giving this incredible overview of botensilimab's role in treating MSS #colorectalcancer. #CancerResearch #Immunotherapy
⭐ We spoke with Dr. Ben Schlechter of Dana-Farber Cancer Institute on the unique mechanisms of action of botensilimab, and how this therapy is well-suited to treat microsatellite stable colorectal cancer, particularly in non-liver metastatic sites. 📺 Dr. Schlechter also highlights how the implications of this research may affect long-term efficacy and durability of response in patients with MSS CRC: https://buff.ly/3RR99vJ
-
That's a wrap on #ESMOGI24! Our team was inspired by engaging with the GI community and sharing the latest advancements from our BOT/BAL therapy, including new data in neoadjuvant colon cancer. Exciting times ahead for the future of cancer care. #Oncology #CancerResearch
-
New data from the NEST clinical trial was just presented at ESMO - European Society for Medical Oncology's #ESMOGI24. The results demonstrated significant tumor reductions in MSS colon cancer patients treated with botensilimab/balstilimab in the neoadjuvant setting. Learn more here: https://lnkd.in/eC6-MfAm
-
The Agenus team is in Munich for ESMO - European Society for Medical Oncology's #ESMOGI24 annual meeting. Stay tuned tomorrow for new data from the NEST clinical trial on our botensilimab/balstilimab #immunotherapy combination in #neoadjuvant colon cancer. See the schedule: https://lnkd.in/ebR3idFf
-
The National Cancer Institute (NCI)'s Cancer Therapy Evaluation Program (CTEP) has announced the availability of our therapy, botensilimab, for clinical studies. Get the details here: https://lnkd.in/ex6zxvJJ
-
If you are a physician attending #ESMOGI24 in Munich from June 26-29, our Medical Affairs team would welcome the opportunity to discuss the future of immuno-oncology with you. Schedule a meeting here: https://lnkd.in/gymm3V-Y
-
We are proud to support Fight Colorectal Cancer’s latest webinar. Tune in tomorrow at 1:00 p.m. ET to hear Smitha Krishnamurthi, M.D., discuss how to navigate the clinical trial landscape and explore treatment options for colorectal cancer. Register to attend: https://lnkd.in/eMNBb5Vt